Mast Therapeutics, Inc. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 7, 2012

Attached files
FileFilename
EX-31.2 - EX-31.2 - Mast Therapeutics, Inc.d338069dex312.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R8.htm
EXCEL - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Mast Therapeutics, Inc.R9.htm
EX-32.1 - EX-32.1 - Mast Therapeutics, Inc.d338069dex321.htm
EX-31.1 - EX-31.1 - Mast Therapeutics, Inc.d338069dex311.htm
10-Q - FORM 10-Q - Mast Therapeutics, Inc.d338069d10q.htm
v2.4.0.6
Stockholders' Equity
 3 Months Ended
Mar. 31, 2012
Stockholders' Equity [Abstract]  
Stockholders' Equity
11. Stockholders’ Equity

Common Stock and Warrant Registered Direct Equity Financing

In January 2011, we completed a registered direct equity financing involving the issuance of units consisting of 8,184,556 shares of our common stock, 5-year warrants to purchase up to an aggregate of 2,046,139 shares of our common stock and 1-year warrants to purchase up to an aggregate of 2,046,139 shares of our common stock. The gross proceeds of this financing were $22.5 million, and we received $21.0 million in net proceeds after deducting the fees and expenses of our placement agent and our other offering expenses. The 1-year warrants expired unexercised in January 2012. We may receive up to $5.6 million of additional proceeds from the exercise of the 5-year warrants. The exercise price of the warrants is $2.75 per share. Subject to certain beneficial ownership limitations, the 5-year warrants are exercisable any time on or before January 11, 2016.

Common Stock and Warrant Underwritten Public Offering

In November 2011, we completed an underwritten public offering of 21,250,000 shares of our common stock and warrants to purchase up to 10,625,000 additional shares of our common stock. These securities were offered and sold to the public in multiples of a fixed combination consisting of one share of our common stock and a warrant to purchase up to 0.5 of a share of our common stock. The gross proceeds from this financing were $17.0 million, and we received $15.6 million in net proceeds after deducting the underwriting commissions and our other offering expenses. We may receive up to $11.7 million of additional proceeds from the exercise of the warrants issued to investors in this financing. The exercise price of the warrants is $1.10 per share. Subject to certain beneficial ownership limitations, the warrants are exercisable at any time on or before November 16, 2016.

We also issued warrants to purchase up to 1,062,500 shares of our common stock at an exercise price of $1.00 per share to the underwriter of the offering and its designees as additional underwriting compensation. These compensation warrants are exercisable at any time on or before April 1, 2015.

Warrants

At March 31, 2012, outstanding warrants to purchase shares of common stock are as follows:

 

                 
Warrants     Exercise Price     Expiration Date
  432,429     $ 56.5000     July 2012
  99,696     $ 11.9125     June 2014
  498,488     $ 8.7475     July 2012
  144,000     $ 5.8750     October 2014
  19,007     $ 4.4750     July 2014
  14,183     $ 4.0625     August 2014
  36,071     $ 3.7500     June 2014
  216,000     $ 3.6700     October 2014
  1,816,608     $ 3.6500     May 2015
  409,228     $ 3.4400     April 2015
  2,046,139     $ 2.7500     January 2016
  1,062,500     $ 1.0000     April 2015
  10,625,000     $ 1.1000     November 2016

 

 

              
  17,419,349              

 

 

              

 

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by Mast Therapeutics, Inc. and has no official or unofficial affiliation with Mast Therapeutics, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.